BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:W. Europe Standard Time BEGIN:STANDARD DTSTART:20251002T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=3;BYMINUTE=0;BYMONTH=10 TZNAME:W. Europe Standard Time TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:20250301T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3 TZNAME:W. Europe Daylight Time TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Time: 10:00 - 12:00 UK time\nPresenters: \;Jessica Purchase \, Group Health Economics Manager (F. Hoffmann-La Roche Ltd\, Welwyn) \;and Monica Daigl\, HTA Statistician and Health Economist (F. Hoffmann-La Roche Ltd\, Basel)\n\n\nAbstract:\nThere is a simple equation for access in the UK: Access = Reimbursement + Uptake\nYet\, whilst a simple and logi cal approach\, each component is challenging to achieve.\nThis webinar foc uses on the National Reimbursement side: the National Institute for Health and Care Excellence (NICE) - who they are\, what is involved in the Healt h Technology Appraisal (HTA) assessment\, how they make decisions.\nWe&rsq uo\;ll also review where the devolved nations come in: how do the Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) differ from NICE in decision making?\nFinally\, through the use of a real world example\, we&rsquo\;ll explore the key drivers and barriers experie nced in decision making: specifically the challenges associated with corre ct comparators and predicting of long term outcomes.\nThis will lead to th e second part of the webinar. We will focus on two advanced statistical te chniques to inform health economic models: modelling of time to event endp oints such as progression free and overall survival beyond the duration of a clinical study to predict long-term outcomes\; and network meta analyse s to estimate the value of a drug in the absence of direct comparative evi dence.\nFinally\, we provide our key recommendations for the future of cli nical trial design\, to support access for the UK market.\n\n\nAbout the P resenters:\n\nJessica Purchase is a Group Health Economics Manager \;i n the Health Economics and \;Strategic Pricing team in Roche UK. She j oined Roche in \;2016\, following 5 years of Health Economics and Mark et Access consulting. In her role she has successfully lead on a variety o f HTAs resulting in UK access in the oncology space.\n\n\n\nMonica Daigl i s a medical statistician and epidemiologist with >\;15 years of experien ce in the analysis of clinical trials and observational studies in pharma\ , medical device industry and academia. She joined 2014 the Global Access Center of Excellence at F. Hoffmann-La Roche as HTA Statistician and Healt h Economist. In her role she supports Roche affiliates with their local HT A submissions in multiple therapeutic areas. \;\nRegistration:\n\n \n \n \;Registration\n \n \n \;PSI Member\n \;Free\n \n \n \;Non-member\n \;£\;20 (plus VAT) \;\n \n \n\n\nRegistration has now closed. DTEND:20190121T110000Z DTSTAMP:20260608T181148Z DTSTART:20190121T090000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Webinar: HTA Submissions in the UK UID:RFCALITEM639165391081662190 X-ALT-DESC;FMTTYPE=text/html:Time: 10:00 - 12:00 UK time\nPresenters: \;Jessica Purchase\, Group Health E conomics Manager (F. Hoffmann-La Roche Ltd\, Welwyn) \;and Mo nica Daigl\, HTA Statistician and Health Economist (F. Hoffmann-La Roc he Ltd\, Basel)
\n
\n\n
Abstract:
\n
There is a si mple equation for access in the UK: Access = Reimbursement + Uptake
\n< p>Yet\, whilst a simple and logical approach\, each component is challengi ng to achieve.
\n
This webinar focuses on the National Reimbursement side: the National Institute for Health and Care Excellence (NICE) - who t hey are\, what is involved in the Health Technology Appraisal (HTA) assess ment\, how they make decisions.
\n
We&rsquo\;ll also review where the devolved nations come in: how do the Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) differ from NICE in decisio n making?
\n
Finally\, through the use of a real world example\, we&r squo\;ll explore the key drivers and barriers experienced in decision maki ng: specifically the challenges associated with correct comparators and pr edicting of long term outcomes.
\n
This will lead to the second part of the webinar. We will focus on two advanced statistical techniques to in form health economic models: modelling of time to event endpoints such as progression free and overall survival beyond the duration of a clinical st udy to predict long-term outcomes\; and network meta analyses to estimate the value of a drug in the absence of direct comparative evidence.
\n
Finally\, we provide our key recommendations for the future of clinical t rial design\, to support access for the UK market.
\n
\n
\nAbout the Presenters:\n

\nJessica Purchase is a Group Health Ec onomics Manager \;in the Health Economics and \;Strategic Pricing team in Roche UK. She joined Roche in \;2016\, following 5 years of He alth Economics and Market Access consulting. In her role she has successfu lly lead on a variety of HTAs resulting in UK access in the oncology space .
\n
\n
\n

\nMonica Daigl is a medical statistician and epidemiologi st with >\;15 years of experience in the analysis of clinical trials and observational studies in pharma\, medical device industry and academia. S he joined 2014 the Global Access Center of Excellence at F. Hoffmann-La Ro che as HTA Statistician and Health Economist. In her role she supports Roc he affiliates with their local HTA submissions in multiple therapeutic are as. \;
\n
Registration:
\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\;Registration
\;PSI Member \;Free
\;Non-member \;£\;20 (plus VAT) \;
\n
\nRegistration has now closed.
END:VEVENT END:VCALENDAR

\;Registration
\;PSI Member	\;Free
\;Non-member	\;£\;20 (plus VAT) \;